Athersys, Inc. (ATHX) Upgraded to Buy by Zacks Investment Research
Zacks Investment Research currently has $1.75 price target on the biopharmaceutical company's stock. According to Zacks, "Athersys is a biopharmaceutical company engaged in the discovery and development of therapeutic product candidates designed to extend and enhance the quality of human life.
from Biotech News
0 Comments